Literature DB >> 22892773

Treatment of common warts with the immune stimulant Propionium bacterium parvum.

Nilton Nasser1.   

Abstract

BACKGROUND: Warts are epithelial proliferations in the skin and mucous membrane caused by various types of HPV. They can decrease spontaneously or increase in size and number according to the patient's immune status. The Propionium bacterium parvum is a strong immune stimulant and immune modulator and has important effects in the immune system and it is able to produce antibodies in the skin.
OBJECTIVE: To show the efficacy of the Propionium bacterium parvum in saline solution in the treatment of skin warts.
METHODS: A randomized double-blind study. Twenty patients with multiple warts were divided into two groups: one received 0,1 ml intradermal injection of placebo solution in just one of the warts and the other received 0,1 ml of saline solution of Propionium bacterium parvum, one dose a month, for 3 to 5 months.
RESULTS: Among the 20 patients who participated in the study, ten received the placebo and ten received the saline solution with Propionium bacterium parvum. In 9 patients treated with the Propionium bacterium parvum solution the warts disappeared without scars and in 1 patient it decreased in size. In 9 patients who received the placebo no change to the warts was observed and in 1 it decreased in size.
CONCLUSIONS: The immune modulator and immune stimulant Propionium bacterium parvum produced antibodies in the skin which destroyed the warts without scars, with statistically significant results (P<0,001), and cured 90 % of the patients. We suggest the use of the immune stimulant in the treatment of warts.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892773     DOI: 10.1590/s0365-05962012000400011

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  7 in total

Review 1.  Immunomodulators in warts: Unexplored or ineffective?

Authors:  Surabhi Sinha; Vineet Relhan; Vijay K Garg
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

2.  First Case Report: Treatment of the Facial Warts by Using Myrtus communis L. Topically on the Other Part of the Body.

Authors:  Mohamad Bagher Minaei; Elham Ghadami Yazdi; Mohamad Ebrahim Zadeh Ardakani; Fataneh Hashem Dabaghian; Ali Mohammad Ranjbar; Mohamad Rastegari; Ali Ghadami Yazdi
Journal:  Iran Red Crescent Med J       Date:  2014-02-05       Impact factor: 0.611

3.  Efficacy of Myrtus communis L. and Descurainia sophia L. Versus Salicylic Acid for Wart Treatment.

Authors:  Elham Ghadami Yazdi; Mohamad Bagher Minaei; Fataneh Hashem Dabaghian; Mohamad Ebrahim Zadeh Ardakani; Ali Mohammad Ranjbar; Mohamad Rastegari; Ali Ghadami Yazdi
Journal:  Iran Red Crescent Med J       Date:  2014-10-05       Impact factor: 0.611

Review 4.  Evolving role of immunotherapy in the treatment of refractory warts.

Authors:  Devinder M Thappa; Minu J Chiramel
Journal:  Indian Dermatol Online J       Date:  2016 Sep-Oct

5.  COVID-19 vaccine and boosted immunity: Nothing ad interim to do?

Authors:  Luca Roncati; Maria Vadalà; Veronica Corazzari; Beniamino Palmieri
Journal:  Vaccine       Date:  2020-10-09       Impact factor: 3.641

Review 6.  The long-standing history of Corynebacterium parvum, immunity, and viruses.

Authors:  Beniamino Palmieri; Maria Vadalà; Luca Roncati; Andrea Garelli; Francesco Scandone; Moreno Bondi; Claudio Cermelli
Journal:  J Med Virol       Date:  2020-06-29       Impact factor: 20.693

Review 7.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.